---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004029"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:54:46.214397+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV

## Summary
- First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.
- Arm evaluates low-dose nivolumab plus VTP-300 boosters after AB-729 and NA therapy to reduce HBsAg in chronic HBV.
- Preliminary data from this arm expected in 2024; original arm data expected H2 2023.
- Enrollment complete in original arm; approximately 20 patients to be enrolled in new open-label arm.

## SEC filing metadata
- accession: 0001171843-23-004029
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/0001171843-23-004029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/f8k_062123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004029
- JSON: https://secwatch.observer/filing/0001171843-23-004029.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.